Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent
- Vineshkumar T Puliyappadamba†1,
- Vino T Cheriyan†1,
- Arun Kumar T Thulasidasan1,
- Smitha V Bava1,
- Balachandran S Vinod1,
- Priya R Prabhu1,
- Ranji Varghese1,
- Arathy Bevin1,
- Shalini Venugopal1 and
- Ruby John Anto1Email author
© Puliyappadamba et al; licensee BioMed Central Ltd. 2010
Received: 18 March 2010
Accepted: 20 August 2010
Published: 20 August 2010
Lung cancer is the most lethal cancer and almost 90% of lung cancer is due to cigarette smoking. Even though nicotine, one of the major ingredients of cigarette smoke and the causative agent for addiction, is not a carcinogen by itself, several investigators have shown that nicotine can induce cell proliferation and angiogenesis. We observed that the proliferative index of nicotine is different in the lung cancer cell lines H1299 (p53-/-) and A549 (p53+/+) which indicates that the mode of up-regulation of survival signals by nicotine might be different in cells with and without p53.
While low concentrations of nicotine induced activation of NF-κB, Akt, Bcl2, MAPKs, AP1 and IAPs in H1299, it failed to induce NF-κB in A549, and compared to H1299, almost 100 times higher concentration of nicotine was required to induce all other survival signals in A549. Transfection of WT-p53 and DN-p53 in H1299 and A549 respectively, reversed the mode of activation of survival signals. Curcumin down-regulated all the survival signals induced by nicotine in both the cells, irrespective of their p53 status. The hypothesis was confirmed when lower concentrations of nicotine induced NF-κB in two more lung cancer cells, Hop-92 and NCI-H522 with mutant p53 status. Silencing of p53 in A549 using siRNA made the cells susceptible to nicotine-induced NF-κB nuclear translocation as in A549 DN-p53 cells.
The present study reveals a detrimental role of nicotine especially in lung cancer patients with impaired p53 status and identifies curcumin as a potential chemopreventive.
Activator protein 1
B-cell lymphoma 2
Cellular Inhibitor of apoptosis protein
Electrophoretic mobility shift assay
Extracellular Signal Regulated Kinase
Inhibitor of apoptosis protein
Inhibitor of kappa B protein alpha
c-Jun N-terminal kinase
MAPK-Mitogen activated protein kinases
Mammalian target of rapamycin
Nuclear factor kappa B
Reticuloendotheliosis Viral Oncogene Homolog A
Small interfering RNA
X-chromosome linked inhibitor of apoptosis
Lung cancer is the most lethal of all cancers worldwide with a dismal prognosis and 5 year survival rate of < 15%. Reports indicate that p53 alterations are the most common genetic events in lung cancer development and 50-60% of non-small cell lung cancers (NSCLC) and 90% of small cell lung cancers (SCLC) contain p53 mutations . The major reason for lung cancer incidence is tobacco smoke, which contains nicotine. There is no evidence indicating that nicotine is a carcinogen by itself ; nevertheless, it has been demonstrated that nicotine promotes the growth of cancer cell populations in the lungs  by stimulating cell proliferation and angiogenesis [4, 5]. Chronic exposure to nicotine causes mitogenic stimulus and leads to the activation of growth-promoting and antiapoptotic signaling pathways such as PI3K-Akt/mTOR, NF-κB, COX-2, Bcl2, MAPKs etc [6–10]. It has also been shown to induce secretion of several growth factors and upregulate the calpain family of proteins in lung cancer cells leading to the activation of Raf/MAPK/ERK pathway [11–13]. Moreover, reports indicate that nicotine inhibits apoptosis induced by various stimuli including chemotherapeutic agents in lung cancer cells where survivin and XIAP are suggested to play a key role .
Curcumin, a polyphenol isolated from Curcuma longa, has been extensively investigated for its cancer chemopreventive and chemotherapeutic properties, which are attributed mainly to its antioxidant and anti-inflammatory potential [15, 16]. Curcumin, with its potent anti-inflammatory property, is expected to exert chemopreventive effects on carcinogenesis and has been shown to modulate numerous transcription factors, protein kinases etc. that have been linked to the pathophysiology of cancer . It up-regulates several apoptosis inducing genes such as p53 and p21  and down-regulates pro-survival genes such as NF-κB, Akt, Bcl2 and Cyclin D1 [17, 18] induced by various stimulants. This has been suggested to be the reason for its chemosensitizing efficacy [17, 19]. Despite the bioavailability of curcumin being very low, studies indicate that even at a physiologically achievable concentration, curcumin is sufficient for its chemopreventive and chemotherapeutic activity .
p53, which regulates many cellular activities including cell cycle arrest and apoptosis, is the most commonly mutated gene in human cancers . It has been well documented that absence of functional p53 in cells render them resistant to chemotherapy, and restoration of p53 lessen the tumor occurrence . One major function of p53 is to control DNA replication by inducing p21 protein, which promotes cell cycle arrest by modifying the phosphorylation of the cyclin-dependent kinases , although regulation of p21 expression independent of p53 also has been reported . Activation of the p53-p21 pathway and induction of both p53 and p21 are often reported in response to DNA damaging agents including nicotine .
The nuclear transcription factor NF-κB is an important survival signal which induces the expressions of diverse target genes including COX-2, Cyclin D1 and XIAP that promote cell proliferation, regulate apoptosis and stimulate invasion and metastasis [9, 26]. Studies indicate that simultaneous inhibition of p53 and NF-κB transcriptional activities decide the fate of the cell [27, 28]. Previous studies have also demonstrated that nicotine activates signal transduction pathways relevant to carcinogenesis through the activations of MAPK and PI3-K/Akt pathways [6, 7].
In the present study we have tried to correlate the effect of nicotine to the p53 status of lung cancer cells, especially NSCLC cell lines of adenocarcinoma or large cell carcinoma origin. We selected these cells for our study because cigarette smoking is a major risk factor in the development of NSCLC, which accounts for 80% of all lung cancers . We report in this study that the induction of survival signals in lung cancer cells by nicotine is dependent on the p53 status of the cells and identify p53 status as an important predictor of lung cancer progression. Additionally, we have attempted in delineating the signaling cross-talk mechanism orchestrating p53-dependent regulation and expression of survival signals such as NF-κB, AP-1, Akt, Bcl2 etc., in the presence and absence of p53 expression. Our findings underscore that p53 plays an essential role in regulating survival signals, especially NF-κB, in response to nicotine. We also present data supporting our contention that curcumin down-regulates all the survival signals induced by nicotine, independent of the p53 status of the cell.
Nicotine induces more proliferation in lung cancer cells lacking p53, which is down-regulated by curcumin
Nicotine induces NF-κB in H1299 cells but not in A549 cells
Nicotine-induced phosphorylation of Akt and over expression of COX-2 and Cyclin D1 in lung cancer cells are inhibited by curcumin
Curcumin prevents the over-expression of IAPs and Bcl2 by nicotine
Nicotine-induced phosphorylation of MAPKs and nuclear translocation of AP-1 in lung cancer cells are down-regulated by curcumin
Regulation of MAPK pathway by nicotine through p53 has already been reported [25, 36]. We therefore assessed whether p53 has any regulatory role in the activation of AP-1, which gets translocated to the nucleus in response to the phosphorylation of MAPKs since, up-regulation of AP-1 activity by nicotine has been reported in the literature . Interestingly, though nicotine failed to activate NF-κB in A549 cells, it activated AP-1 very efficiently in both H1299 and A549 cells (Fig. 5E-F) though the pattern of nuclear translocation of AP-1 was in parallel with the phosphorylation pattern of MAPKs in the respective cell lines. As in the case of MAPKs, curcumin treatment down regulated this activation almost completely in both the cells (Fig. 5G-H).
Introduction and inactivation of p53 in H1299 and A549 cells respectively, bring about reciprocal effect on the activation pattern of NF-κB, MAPKs and AP-1 in both the cells
Proliferative as well as clonogenic potential induced by nicotine may be regulated through up-regulation of p53 and p21, and is down-regulated by curcumin
As part of investigation of this difference in the activation pattern of various survival signals by nicotine in cells with and without p53, we evaluated the effect of nicotine on expression levels of p53 and p21 in A549 parental and A549-p53 DN cells. Interestingly, while lower concentrations (10-9 M - 10-7 M) of nicotine induced over-expression of p53 and p21 in A549 cells, it failed to induce significant changes in the expression pattern of p53 and p21 in A549-p53 DN cells (Fig. 7C-D). To check whether p53 is the only molecule regulating the p21 signaling in A549 cells, we also investigated the expression status of p21 in response to nicotine in H1299 cells. We did not find any significant difference in the expression of p21 in H1299 cells (Fig. 7E), implying that p53 is the key regulator of p21 in nicotine-induced signaling events. To confirm this hypothesis, we checked the p21 status in H1299-p53 WT cells in response to nicotine. As in the case of A549 cells, a strong induction of p53 was produced by nicotine in these cells (Fig. 7E) which confirms the regulatory role of p53 in nicotine-induced p21 expression.
Loss of function of p53 enhances nicotine-induced proliferation and NF-κB nuclear translocation in lung cancer cells
Enormous efforts have been devoted by various research groups to identify the role of nicotine in the process of carcinogenesis by tobacco. It has been implicated as a potential risk factor in the proliferation of various cancer cells [14, 41] and has been shown to induce enhanced tissue perfusion and angiogenesis [5, 42]. In the present study, we have convincingly shown that nicotine induces proliferation in lung cancer cells, especially in those with impaired p53 status. It also induces an array of antiapoptotic factors in these cells. Although nicotine has been shown to induce proliferation in lung cancer cells , the regulatory role of p53 on nicotine-induced proliferation has not yet been addressed. We observed a significant increase in the proliferation of lung cancer cells lacking p53. This established a ground for us to evaluate the effect of p53 in the induction of various survival signals by nicotine.
The relation between NF-κB and p53 is controversial. Conceptually, over-expression of NF-κB is linked to the development and progression of various tumors  and inhibition of NF-κB function allegedly suppress tumorigenesis and leads to the regression of tumors. It has been documented that both NF-κB and p53 compete for the transcriptional co-activators . Recent reports suggest that the presence of p53 prevents NF-κB activation though, the mechanism is not clear. However, contradicting these observations, p53-induced NF-κB activation has also been reported . It has also been shown that inhibition of p53 does not inhibit NF-κB function .
In our present study we observed a strong activation of NF-κB by nicotine in the p53 null H1299 cell line, while no significant activation of the same was noted in the p53 proficient A549 cells, at any of the concentrations studied. Zhang et al have reported that pre-treatment with 100 μM nicotine up-regulate both mRNA and protein level expression of NF-κB in A549. However, supporting our observation, Moodie et al have reported that cigarette smoke condensate, in which nicotine is one of the major components (0.3 mg/cigarette), failed to induce NF-κB in A549 cells.
A cross-talk between Akt and p53 acting as cell control machinery for switching between survival and death has been reported. Akt activation has also been reported in p53 null cells . In our study, 10-9M - 10-8M nicotine induced phosphorylation of Akt in H1299 cells. In contrast, a 100 fold higher concentration of nicotine was required to produce similar effects in A549. Several reports indicate interdependence between NF-κB and Akt . However, Akt independent activation of NF-κB has also been reported . In the present study we noted a strong phosphorylation of Akt by nicotine in A549 cells, although it failed to induce NF-κB in A549. This indicates that, nicotine-induced Akt phosphorylation is independent of NF-κB activation status of the cell.
No clear consensus between p53 and COX-2 exists in the literature. While some studies show that p53 up-regulates COX-2 , others show that p53 down-regulates it . We observed induction of COX-2 by nicotine in A549 cells though it failed to induce NF-κB, strengthening the notion that nicotine-induced COX-2 activation in A549 cells is independent of NF-κB. Even though COX-2 is generally considered as an NF-κB dependent gene , there are studies which report the activation of COX-2 independent of NF-κB . In parallel, we observed an NF-κB and p53 independent induction of Cyclin D1 by nicotine, though the expression profile was less in A549 cells. Cyclin D1 is also considered as an NF-κB dependent gene  although, recent studies implicate Cyclin D1 expression through pathways independent of NF-κB .
IAP family of proteins is another essential target of NF-κB . The present study as well as a previous study by Dasgupta et al, have noticed over-expression of IAPs by nicotine in A549 and H1299 cells. Of interest, this is the first study reporting the difference in the activation pattern of IAPs between both these cell lines. Bcl2 is another molecule which has a key role in regulating nicotine-induced survival signaling and has often been considered as NF-κB dependent. Interestingly, we observed Bcl2 up-regulation in both the cell lines, though the pattern of up-regulation varied between cell lines. In rapport to our observation, a novel nicotine-stimulated survival pathway that involves Bcl2 phosphorylation through MAPK pathway has been reported earlier .
Nicotine also induces p53  which, often regulates the phosphorylation pattern of MAPKs [36, 51]. On the contrary, another study reports that MAPK activation occurs only in cells with functional p53 , indicating a reciprocal interaction between p53 signaling pathway and MAPK pathway. We observed a discrete difference in the phosphorylation pattern of MAPKs in both the cells. The involvement of p53 was further confirmed when the phosphorylation pattern was reversed when p53 was inactivated in A549 and introduced in H1299 cells.
AP-1 is a transcriptional regulator and phosphorylation of MAPKs leads to nuclear translocation of AP-1 . Although NF-κB and AP-1 are regulated by different mechanisms, several studies indicate that they are activated simultaneously . Nicotine induced nuclear translocation of AP-1 in both the cell lines, even though it failed to induce NF-κB in A549. However, as in the case of MAPKs, depending on the p53 status of the cell line, there was a significant change in the activation pattern of AP-1. In support of the involvement of p53 in AP1 activation, the nuclear translocation pattern of AP-1 was reversed in A549-p53DN and H1299-p53WT cells.
The ability of nicotine to enhance adherence-independent proliferation of tumor cells is well documented . We observed a marked difference in the number and size of the clones between both H1299 and A549 cells treated with nicotine, which was strongly corroborating within the concentration range of nicotine at which the survival signals are activated in both the cells, implicating a regulatory role of these survival signals on nicotine-induced enhancement of clonogenic potential. As there was a drastic reduction in the number of clones on treatment with curcumin in both the cells, it is also evident that curcumin inhibits the effect of nicotine by down-regulating these survival signals. Nicotine has a high toxicity in comparison to many other alkaloids such as cocaine and higher doses of nicotine have been reported to be lethal (0.5-1.0 mg/kg for adult humans, and 10 mg for children) . In our study, we also observed that all the survival signals induced by nicotine are abrogated at higher concentrations suggesting that there may be a balance between the pro-survival and anti-survival signals induced by this compound at different concentrations. However the exact concentration at which this switching over occurs is still unclear as we observed the cessation of various survival signals at different concentrations of nicotine.
Activation of almost all the survival signals investigated in this study is involved in the process of lung cancer progression. It has also been shown that p53 and p21 negatively regulate these survival signals [28, 47, 23]. Induction of p53 and its downstream target p21 by nicotine has been correlated to the inhibition of cell proliferation by nicotine . We observed a strong induction of p53 as well as p21 by lower concentrations of nicotine in A549 cells which may be the reason for the absence of proliferative signals at this concentration in these cells. A strong induction of p21 was noted in response to nicotine in H1299 cells transfected with wild type p53 as well. But we did not observe any change in the expression of p53 in A549-p53DN cells. This is expected since p53 is non-functional in these cells, and hence cannot regulate the expression of p21. Similarly, no difference in expression of p21 in response to nicotine treatment was noted in H1299 cells as well as A549-p53DN cells, again confirming the role of p53 in regulating the nicotine-induced signaling events. Hence, we hypothesize that the induction of p53 and p21 by lower concentrations of nicotine in A549 cells may be one of the reasons why nicotine failed to induce these survival signals at these concentrations in A549, though further studies are required to confirm this hypothesis.
Our hypothesis that p53 is the key regulator of nicotine-induced survival signaling in lung cancer cells, was further authenticated in two more lung cancer cells with mutant p53 status. Lower concentrations of nicotine induced proliferation in these cells and pre-treatment with curcumin prevented it and, as in H1299, lower concentrations of nicotine induced NF-κB nuclear translocation in these cells too. In addition, when p53 was silenced in A549 cells by p53 siRNA, as in A549-p53 DN cells, nicotine induced a strong nuclear translocation of NF-κB, while co-transfection of these cells with WT p53 completely inhibited the same, substantiating the regulatory role of p53 in nicotine signaling.
The data obtained from our study is very significant because the average plasma level concentration of nicotine in a typical pack per day smoker is between 20-40 mg . Studies have indicated that chemotherapeutic drugs like cisplatin, which induce p53 in cells with a wild-type p53 gene can induce apoptosis in these cells while cells with mutated p53 are unaffected . Supporting this observation, Dasgupta et al have shown that nicotine prevents the cisplatin-induced apoptosis in A549 cells with active p53. We also disclose a detrimental role of nicotine in lung cancer patients with mutant p53 status. Hence our study has proved beyond doubt that p53 has a significant role in regulating the survival signals induced by nicotine in lung cancer cells. It is also clear that curcumin down-regulates these survival signals induced by nicotine in both the cells, independent of their p53 status.
Our study identifies nicotine as a potential tumor promoter, especially in people with impaired p53 status and illustrates a chemopreventive role to curcumin against nicotine-induced lung cancer progression.
H1299 cell line was a gift from Prof. BB Aggarwal, MD Anderson, Houston, A549 and NCI-H522 cells were procured from NCCS, Pune, and Hop-92 was obtained from NCI, Bethesda, MD.
Antibodies against p53, IκBα, XIAP and cIAP-1 and phosphospecific antibodies against-IKK, p38, Akt and p42/44 were purchased from Cell Signalling (Beverly, MA) and those against p50, RelA, pJNK, COX-2 and Survivin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). G418 and pifithrin-α were procured from Calbiochem (San Diego, USA). Lipofectamine was procured from Invitrogen (Carlsbad, CA) and control siRNA and p53 siRNA were procured from Dharmacon, Inc (Chicago, IL). All other chemicals were purchased from Sigma Chemicals (St. Louis, MO).
Mode of treatment
In all combination treatments 10 μM curcumin was added 2 h before nicotine (10-8 M in H1299 and 10-6 M in A549).
Proliferative/cytotoxic effect of nicotine and/or curcumin was determined by MTT assay as described earlier .
[3H] Thymidine incorporation
For [3H] thymidine incorporation assay, cells were seeded in 96 well plates and treated with required concentrations of the drugs. After 18 h of incubation, [3H] thymidine was added (0.5 μCi/well) and further incubated for 6 h. Then the culture medium was removed, the cells were washed twice with phosphate-buffered saline (PBS), treated with 5% trichloroacetic acid, pelleted and supernatant was removed. Cells were then washed with ethanol and solubilized with 0.2N NaOH, contents of each well were mixed with 3 ml scintillation fluid and the radioactivity was counted using a liquid scintillation counter . The experiment was repeated thrice and the error bars indicate standard deviation.
Electrophoretic Mobility Shift Assay (EMSA)
To detect activation of NF-κB and AP-1, EMSA was done and visualized by a Phosphor Imager (Bio-Rad Personal FX). The specificity of the bands were confirmed by super shift .
Isolation of Plasmids
The plasmids were isolated by the standard alkaline lysis method .
H1299 Cells were transfected with pcDNA3-p53WT or the empty vector pcDNA3 while A549 cells were transfected with pcDNA3-p53 DN or the empty vector pcDNA3 using the calcium-phosphate transfection kit (Life Technologies, Inc.) according to manufacturer's protocol and selected using G418 (150 μg/ml) .
A549 cells were transiently transfected with control siRNA, p53 siRNA and/or WT-p53 plasmid using lipofectamine 2000 reagent according to manufactures protocol (Invitrogen).
The total protein after treatment with nicotine and/or curcumin was electroblotted as described earlier  and developed by Enhanced Chemiluminescence (Immobilon Western, Miliipore, Billerica, MA).
The cells were treated with nicotine and/or curcumin for 72 h, as in MTT assay after which the cells were split and seeded in six well plates and clonogenic assay was done as described by Franken et al.
Statistical significance was calculated using one-way ANOVA followed by Tukey post-hoc analysis.
We thank Bert Vogelstein, Philip D Perkins and Ghana Shyam Swarup for the p53 plasmids, Tessy T Maliekal for technical advice and Gayathri LT and Jayesh Antony for technical assistance. The authors acknowledge with thanks, Christine Wojewade (USA) and Sophia Margaret Joseph for Editorial corrections.
- D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R, Gazdar A, Minna JD: High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene. 1992, 7: 339-346.PubMed
- Waldum HL, Nilsen OG, Nilsen T, Rørvik H, Syversen V, Sanvik AK, Haugen OA, Torp SH, Brenna E: Long-term effects of inhaled nicotine. Life Sciences. 1996, 58: 1339-1346. 10.1016/0024-3205(96)00100-2View ArticlePubMed
- Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP: A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Inves. 2002, 110: 527-536.View Article
- Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, Chellappan S: Nicotine induces cell proliferation by β-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest. 2006, 116: 2208-2217. 10.1172/JCI28164PubMed CentralView ArticlePubMed
- Egleton RD, Brown KC, Dasgupta P: Angiogenic activity of nicotinic acetylcholine receptors: Implications in tobacco related vascular diseases. Pharmacol Ther. 2009, 121: 205-223. 10.1016/j.pharmthera.2008.10.007View ArticlePubMed
- West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA: Tobacco carcinogen-induced cellular transformation increases activation of the Phosphatidylinositol 3'-Kinase/Akt pathway in Vitro and in Vivo. Cancer Res. 2004, 64: 446-451. 10.1158/0008-5472.CAN-03-3241View ArticlePubMed
- Zhang T, Lu H, Shang X, Tian Y, Zheng C, Wang S, Cheng H, Zhou R: Nicotine prevents the apoptosis induced by menadione in human lung cancer cells. Biochem Biophys Res Comm. 2006, 342: 928-934. 10.1016/j.bbrc.2006.02.047View ArticlePubMed
- Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA: Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis. 2005, 26: 1182-1195. 10.1093/carcin/bgi072View ArticlePubMed
- Shin VY, Wu WK, Chu KM, Wong HP, Lam EK, Tai EK, Koo MW, Cho CH: Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol Cancer Res. 2005, 3: 607-615. 10.1158/1541-7786.MCR-05-0106View ArticlePubMed
- Mai H, May WS, Gao F, Jin Z, Deng X: A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. J Bio Chem. 2003, 278: 1886-1891. 10.1074/jbc.M209044200.View Article
- Tsai JR, Chong IW, Chen CC, Lin SR, Sheu CC, Hwang JJ: Mitogen-activated protein kinase pathway was significantly activated in human bronchial epithelial cells by nicotine. DNA Cell Biol. 2006, 25: 312-322. 10.1089/dna.2006.25.312View ArticlePubMed
- Arredondo J, Chernyavsky AI, Grando SA: The nicotinic receptor antagonists abolish pathobiologic effects of tobacco-derived nitrosamines on BEP2D cells. J Cancer Res Clin Oncol. 2006, 132: 653-663. 10.1007/s00432-006-0113-9View ArticlePubMed
- Arredondo J, Chernyavsky AI, Grando SA: Nicotinic receptors mediate tumorigenic action of tobacco-derived nitrosamines on immortalized oral epithelial cells. Cancer Biol Ther. 2006, 5: 511-517. 10.4161/cbt.5.5.2601View ArticlePubMed
- Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S: Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and Survivin. Proc Natl Acad Sci. 2006, 103: 6332-6337. 10.1073/pnas.0509313103PubMed CentralView ArticlePubMed
- Sharma RA, Gescher AJ, Steward WP: Curcumin: The story so far. Eur J Cancer. 2005, 41: 1955-1968. 10.1016/j.ejca.2005.05.009View ArticlePubMed
- Oyama Y, Masuda T, Nakata M, Chikahisa L, Yamazaki Y, Miura K, Okagawa M: Protective actions of 5'-n-alkylated curcumins on living cells suffering from oxidative stress. Eur J Pharmacol. 1998, 360: 65-71. 10.1016/S0014-2999(98)00635-9View ArticlePubMed
- Aggarwal BB, Kumar A, Aggarwal MS, Shisodia S: Curcumin derived from turmeric Curcuma longa: a spice for all seasons. Phytopharmaceuticals in Cancer Chemoprevention. Edited by: Bagchi D, Preuss HG. 2005, 349-387. Boca Raton: CRC Press,
- Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB: Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome C release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis. 2002, 23: 143-150. 10.1093/carcin/23.1.143View ArticlePubMed
- Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ: Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem. 2005, 280: 6301-6308. 10.1074/jbc.M410647200View ArticlePubMed
- Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A: Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced Prostaglandin E2 production. Cancer Res. 2001, 61: 1058-1064.PubMed
- Arakawa H: p53, apoptosis and axon-guidance molecules. Cell Death Differ. 2005, 12: 1057-1065. 10.1038/sj.cdd.4401601View ArticlePubMed
- Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med. 2002, 8: 282-288. 10.1038/nm0302-282View ArticlePubMed
- Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE, Bittigau P, Felderhoff-Mueser U, Kaindl AM, Bührer C, Hansen HH, Stryjecka-Zimmer M, Turski L, Ikonomidou C: NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci. 2005, 102: 15605-15610. 10.1073/pnas.0507679102PubMed CentralView ArticlePubMed
- Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995, 9: 935-944. 10.1101/gad.9.8.935View ArticlePubMed
- Berger F, Gage FH, Vijayaraghavan S: Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells. J Neurosci. 1998, 18: 6871-6881.PubMed
- Meng F, Liu L, Chin PC, D'Mello SR: Akt is a downstream target of NF-κB. J Biol Chem. 2002, 277: 29674-29680. 10.1074/jbc.M112464200View ArticlePubMed
- Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, Camandola S, El-Metainy S, Behnke H, Mattson MP, Krieglstein J: Reciprocal inhibition of p53 and nuclear factor-κB transcriptional activities determines cell survival or death in neurons. J Neurosci. 2003, 23: 8586-8595.PubMed
- Webster GA, Perkins ND: Transcriptional cross talk between NF-κB and p53. Mol Cell Biol. 1999, 19: 3485-3495.PubMed CentralView ArticlePubMed
- Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB: Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degradation of IκBα: correlation with induction of cyclooxygenase-2. Carcinogenesis. 2002, 23: 1511-1518. 10.1093/carcin/23.9.1511View ArticlePubMed
- Sudheerkumar P, Shiras A, Das G, Jagtap JC, Prasad V, Shastry P: Independent activation of Akt and NF-kappaB pathways and their role in resistance to TNF-α mediated cytotoxicity in gliomas. Mol Carcinog. 2008, 47: 126-136. 10.1002/mc.20372View ArticlePubMed
- Biliran H, Banerjee S, Sarkar FH, Thakur A, Bollig A, Ahmed F, Wu J, Sun Y, Liao JD: c-Myc-induced chemosensitization is mediated by suppression of Cyclin D1 expression and NF-κB activity in pancreatic cancer cells. Clin Cancer Res. 2007, 13: 2811-2821. 10.1158/1078-0432.CCR-06-1844View ArticlePubMed
- Klein EA, Yang C, Kazanietz MG, Assoian RK: NFκB-independent signaling to the Cyclin D1 gene by Rac. Cell Cycle. 2007, 6: 1115-1121.View ArticlePubMed
- Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP-1 and c-IAP2 to suppress Caspase-8 activation. Science. 1998, 281: 1680-1683. 10.1126/science.281.5383.1680View ArticlePubMed
- Chu M, Guo J, Chen CY: Long-term exposure to nicotine, via Ras pathway, induces Cyclin D1 to stimulate G1 cell cycle transition. J Biol Chem. 2005, 280: 6369-6379. 10.1074/jbc.M408947200View ArticlePubMed
- Furusu A, Nakayama K, Xu Q, Konta T, Kitamura M: MAP Kinase-dependent, NFκB-independent regulation of inhibitor of apoptosis protein genes by TNF-α. J Cell Physiol. 2007, 210: 703-710. 10.1002/jcp.20881View ArticlePubMed
- Zhang H, Shi X, Zhang QJ, Hampong M, Paddon H, Wahyuningsih D, Pelech S: Nocodazole-induced p53-dependent c-Jun N-terminal Kinase activation reduces apoptosis in Human colon carcinoma HCT116 Cells. J Biol Chem. 2002, 277: 43648-43658. 10.1074/jbc.M203214200View ArticlePubMed
- Wang X, Bacher B, Hollt V: Nicotine-induced gene expression of proenkephalin in bovine chromaffin cells. Clin Invest. 1994, 72: 925-929. 10.1007/BF00190754.View Article
- Ryan KM, Ernst MK, Rice NR, Vousden KH: Role of NF-kappaB in p53-mediated programmed cell death. Nature. 2000, 404: 892-897. 10.1038/35009130View ArticlePubMed
- Bohuslav J, Chen LF, Kwon H, Mu Y, Greene WC: p53 induces NF-κB activation by an IκB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 Kinase 1. J Biol Chem. 2004, 279: 26115-26125. 10.1074/jbc.M313509200View ArticlePubMed
- Tanaka Y, Ota K, Kameoka M, Itaya A, Yoshihara K: Up-regulation of NFκB-responsive gene expression by ΔNp73α in p53 null cells. Exp Cell Res. 2006, 312: 1254-1264. 10.1016/j.yexcr.2005.12.013View ArticlePubMed
- Chen RJ, Ho YS, Guo HR, Wang YJ: Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci. 2008, 104: 283-293. 10.1093/toxsci/kfn086View ArticlePubMed
- Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP: Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 2001, 7: 833-839. 10.1038/89961View ArticlePubMed
- Nakshatri H, Nakshatri PB, Martin DA, Goulet RJ, Sledge GW: Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997, 17: 3629-3639.PubMed CentralView ArticlePubMed
- Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, Hay N: Activation of Akt/Protein Kinase B Overcomes a G2/M Cell Cycle Checkpoint Induced by DNA Damage. Mol Cell Biol. 2002, 22: 7831-7841. 10.1128/MCB.22.22.7831-7841.2002PubMed CentralView ArticlePubMed
- Moodie FM, Marwick JA, Anderson CS, Szulakowski P, Biswas SK, Bauter MR, Kilty I, Rahman I: Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-κB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J. 2004, 18: 1897-1899.PubMed
- Han JA, Kim JI, Ongusaha PP, Hwang DH, Ballou LR, Mahale A, Aaronson SA, Lee SW: p53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J. 2002, 21: 5635-5644. 10.1093/emboj/cdf591PubMed CentralView ArticlePubMed
- Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ: Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 1996, 56: 4424-4429.PubMed
- Zhang D, Li J, Song L, Ouyang W, Gao J, Huang C: A JNK1/AP-1-Dependent, COX-2 Induction Is Implicated in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Cell Transformation through Regulating Cell Cycle Progression. Mol Cancer Res. 2008, 6: 165-174. 10.1158/1541-7786.MCR-07-0181View ArticlePubMed
- Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS: NF-κB controls cell growth and differentiation through transcriptional regulation of Cyclin D1. Mol Cell Biol. 1999, 19: 5785-5799.PubMed CentralView ArticlePubMed
- LaCasse EC, Baird S, Korneluk RG, MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998, 17: 3247-3259. 10.1038/sj.onc.1202569View ArticlePubMed
- Gulati AP, Yang YM, Harter D, Mukhopadhyay A, Aggarwal BB, Benzil DL, Whysner J, Albino AP, Murali R, Jhanwar-Uniyal M: Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-κb, but not c-jun n-terminal kinase and activated protein-1. Mol Carcinog. 2006, 45: 26-37. 10.1002/mc.20149View ArticlePubMed
- Lee SW, Fang L, Igarashi M, Ouchi T, Lu KP, Aaronson SA: Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. Proc Natl Acad Sci. 2000, 97: 8302-8305. 10.1073/pnas.150024397PubMed CentralView ArticlePubMed
- Zhong CY, Zhou YM, Douglas GC, Witschi H, Pinkerton KE: MAPK/AP-1 signal pathway in tobacco smoke-induced cell proliferation and squamous metaplasia in the lungs of rats. Carcinogenesis. 2005, 26: 2187-2195. 10.1093/carcin/bgi189View ArticlePubMed
- Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, Li Z, Evans DB, Abbruzzese JL, Chiao PJ: NF-κB and AP-1 connection: Mechanism of NF-κB-dependent regulation of AP-1 activity. Mol Cell Biol. 2004, 24: 7806-7819. 10.1128/MCB.24.17.7806-7819.2004PubMed CentralView ArticlePubMed
- Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S, Carless M, Kim E, Coppola D, Haura E, Chellappan S: Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer. 2009, 124: 36-45. 10.1002/ijc.23894PubMed CentralView ArticlePubMed
- Okamoto M, Kita T, Okuda H, Tanaka T, Nakashima T: Effects of aging on acute toxicity of nicotine in rats. Pharmacol Toxicol. 1994, 75: 1-6. 10.1111/j.1600-0773.1994.tb00316.xView ArticlePubMed
- Benowitz NL, Hall SM, Herning RI, Jacob P, Jones RT, Osman AL: Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med. 1983, 309: 139-142. 10.1056/NEJM198307213090303View ArticlePubMed
- Zamble DB, Jacks T, Lippard SJ: p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci. 1998, 95: 6163-6168. 10.1073/pnas.95.11.6163PubMed CentralView ArticlePubMed
- Anto RJ, Maliekal TT, Karunagaran D: L-929 cells harboring ectopically expressed RelA resist curcumin-induced apoptosis. J Biol Chem. 2000, 275: 15601-15604. 10.1074/jbc.C000105200View ArticlePubMed
- Bimboim HC, Doly J: A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucl Acids Res. 1979, 7: 1513-1523. 10.1093/nar/7.6.1513View Article
- Anto RJ, Venkatraman M, Karunagaran D: Inhibition of NF-κB sensitizes A431 cells to epidermal growth factor-induced apoptosis, whereas its activation by ectopic expression of RelA confers resistance. J Biol Chem. 2003, 278: 25490-25498. 10.1074/jbc.M301790200View ArticlePubMed
- Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C: Clonogenic assay of cells in vitro. Nat Protoc. 2006, 1: 2315-2319. 10.1038/nprot.2006.339View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.